A Phase 0 Study of AZD1775 in Recurrent GBM Patients
A Phase 0 Study of AZD1775 in Preoperative Glioblastoma Multiforme (GBM) Patients Scheduled for Resection to Evaluate for Central Nervous System (CNS) Penetration
Sponsor: American Society of Clinical Oncology
This EARLY_PHASE1 trial investigates GBM and Glioblastoma and is currently completed. American Society of Clinical Oncology leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed EARLY_PHASE1
Status: Unknown Status → Completed
-
Feb 2019 — Jan 2021 [monthly]
Unknown Status EARLY_PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting EARLY_PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting EARLY_PHASE1
Phase: Phase 0 → EARLY_PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting Phase 0
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American Society of Clinical Oncology
- Barbara Ann Karmanos Cancer Institute
- St. Joseph's Hospital and Medical Center, Phoenix
- The Ben & Catherine Ivy Foundation
- Translational Genomics Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .